



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

2019 Annual Results

March 2020



Disclaimer

The information in this presentation has been prepared by China Resources Pharmaceutical Group Limited (the "Company") for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Company.

Although care has been taken to ensure that the facts stated in this document are accurate, and that the opinions expressed are fair and reasonable, the contents of this document have not been independently verified and certain information contained in this document may differ from the Company's disclosure documents. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. None of the Company nor any of its directors, employees or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof.

It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its representatives are under an obligation to update, revise or affirm.

The information communicated in this presentation contain certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company's operations and factors beyond the Company's control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. In particular, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this document. The Company shall not have (a) any obligation to update on further changes to such information or to correct any inaccuracies or omissions in this document nor (b) any liability in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

This presentation and the information contained herein do not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall they or any part of them form the basis of or be relied on in connection with any contract or commitment whatsoever. . The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any State securities laws in the United States and may not be offered, sold or delivered within the United States absent from registration under or an applicable exemption from the registration requirements of the United States securities laws.

The contents of this document have not been reviewed by any regulatory authority in any jurisdiction. This presentation and the information contained herein are being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, PRC, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws.

No invitation is made by this presentation or the information contained herein to enter into, or offer to enter into, any agreement to purchase, acquire, dispose of, subscribe for or underwrite any securities or structured products, and no offer is made of any shares in or debentures of a company for purchase or subscription except as permitted under the laws of Hong Kong. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent (a) are either (i)a "qualified institutional buyer" (within the meaning of Regulation 144A under the Securities Act), or (ii) outside of the United States; and (b) are "professional investors" as defined in the Securities and Futures Ordinance (Cap 571 Laws of Hong Kong) and any rules made under that Ordinance.

This presentation and the information contained herein are strictly confidential. You are agreeing to maintain absolute confidentiality regarding the information contained in this presentation. These materials are given to you solely for your own use and information and no part of this document may be copied or reproduced or redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) in any manner or published, in whole or in part, for any purpose. Any failure to comply with these limitations may constitute a violation of law and may lead to legal or regulatory action.

1

2019 Highlights

2

Business Review

3

Financial Review

4

2020 Strategy

5

Appendix




2019 Overall Financial Performance

HK\$ mn	2019	2018	YoY (HKD)	YoY (RMB)
Revenue	204,454	189,689	7.8%	12.6%
Gross Profit	34,018	34,930	-2.6%	1.7%
Operating Profit	9,156	11,696	-21.7%	-18.2%
Net Profit	5,098	7,572	-32.7%	-29.7%
Net Profit Attributable to Shareholders	3,286	3,978	-17.4%	-13.7%
EPS (HKD)	0.52	0.63		

Achievements Since Listing

Facing the drastic changes in the industry and market, CR Pharma quickly established a biopharmaceutical platform, strived to enrich the R&D pipeline, efficiently completed the integration and strategy review of CR Jiangzhong, reshaped the R&D innovation system, actively promoted model innovation and synergetic development between different business segments, and continuously improved operational quality. The Group has achieved solid results since its listing on the Hong Kong's main board in October, 2016

- Business scale and total assets **ranked third in the industry**
- Established an organizational structure led by R&D and innovation, **spun off CR Biopharm, and NIP¹, the new drug development platform, took shape**
- **Completed multiple equity investment projects**, including CR Jiangzhong, which increased the total revenue of the Group
- **Established a pharmaceutical industry fund** and completed multiple project including Fusen Pharmaceuticals
- **56 products from the manufacturing segment exceeded HK\$100 million in sales, including 5 surpassed HK\$1 billion in sales**, ranking fifth in the PRC pharmaceutical manufacturing industry
- **Accelerated development of distribution business**: covered 28 provinces, business scale ranked among top three in over 10 provinces
- **Actively promoted international cooperation**, formed strategic partnerships with multiple multinational pharmaceutical enterprises, such as Sanofi, Takeda and Gilead Sciences
- Constantly innovated business models, **self-established e-commerce platform, CR Pharma e-Store (润药商城)**, has gone live in 20 provinces
- Actively promoted **intelligent manufacturing upgrade**, with subsidiary CR Sanjiu explored intelligent manufacturing of traditional Chinese medicine, subsidiary Dong-E-E-Jiao's smart factory achieved a self-control rate of 95%, and subsidiary CR Jiangzhong owns a world-leading unmanned production line for Chinese medicine liquid preparation



CR Pharma and its subsidiaries were included in:

- 2019** All three A-share listed subsidiaries were included in the FTSE Russell Global Index
- 2018** Hang Seng Stock Connect Index
- 2017** Hang Seng Composite Large Cap Index, FTSE Global Equity Index (Large Cap), Morgan Stanley Capital International (MSCI) China

Manufacturing

Segment revenue: HK\$33.8 bn
Segment gross profit: HK\$21.4 bn


Distribution

Segment revenue: HK\$170.7 bn
Segment gross profit: HK\$11.7 bn

Retail

Segment revenue: HK\$6.5 bn
Segment gross profit: HK\$0.8 bn

Segment Revenue (HK\$ bn)



- Focused on core TA areas and products
- Strengthened brand advantages in CHC¹ area and strengthened business collaboration with renowned pharmaceutical MNCs
- Established a chronic disease management platform and accelerate network penetration
- Increased investment in R&D and accelerate the introduction of new products
- Sped up intelligent industrial upgrade

- Transformed from distribution to service cooperation, and actively participated in centralized procurement
- Leveraged on the advantages and values of nationwide network, strengthened port construction and import drug introduction
- Accelerated the introduction of premium innovative drugs
- Promoted professional development of medical device distribution business and CR Pharma e-store (潤藥商城)

- Seized the development opportunity from "prescription outflow", accelerated expansion of DTP pharmacy network
- Integrated retail resources, forged professional retail pharmacy brand "Teck Soon Hong"
- Developed new retail, and pharmacies combined with medicine and clinic, and cooperated with WeChat, JD, etc.

Completed integration of biopharma platform, made a breakthrough development in innovative drugs

- Spun-off CR Biopharm
- “Rui Tong Li” were included in the 2019 NRDL
- 3 products on the biopharmaceutical platform is on the market, 14 are in pipeline, including 8 innovative drugs
- Class I innovative drug NIP292 was approved for investigational new drug (IND) and was granted the Orphan Drug Designation (ODD) in the U.S.

Completed several high-quality mergers and acquisitions and significantly enhanced competitiveness in each business segment

- Completed CR Jiangzhong's mergers and acquisitions, strengthened leading position in the OTC market
- In November 2019, CR Sanjiu acquired 100% equity interest in Aonuo Pharmaceutical to build a leading brand in child health
- Completed the subscription and acquired total 20% stake in Zhejiang Int’L Group to enhance CR Pharma’s comprehensive competitiveness in the East China region
- CR Pharmaceutical Retail Group acquired 25% stake in Tycoon Group Holdings Limited, strengthening CR Pharma’s competitive advantage in distribution and retail business in Hong Kong

Realized the synergy effect from the integrated layout and effectively improve the operation quality

- Established “CR Pharmaceutical OTC Strategic Synergy Committee” to promote synergy in the OTC businesses
- CR Sanjiu and CR Jiangzhong have made good progress on the collaborative project of TCM formula granules, signed a strategic cooperation agreement, and established a sales JV
- CR Pharmaceutical Commercial’s retail segment and CR Land jointly promoted synergetic development in senior home business



Manufacturing segment signed multiple international business cooperation agreements to accelerate the upgrade and expansion of product portfolio, bringing momentum to the expansion of sales scale and future high growth

- 15 international cooperation projects were negotiated, involving original drug, generic drug, OTC drug and healthcare product, etc.
- Signed exclusive agreement with Takeda Pharmaceutical for distributing product “Alinamin” in mainland China
- Acquired exclusive agency rights in China for products under Australian Nature’s Care pro series
- Obtained exclusive distribution rights in mainland China from Japanese Ryukakusan for its products

- 1 2019 Highlights
- 2 **Business Review**
- 3 Financial Review
- 4 2020 Strategy
- 5 Appendix




- Manufacturing segment revenue in 2019 was HK\$33.8bn, increased 0.8% in terms of RMB, mainly due to the impact from Dong-E-E-Jiao's channel inventory reduction and decreasing annual results
- In 2019, chemical drugs, TCM, biological drugs and nutritional & healthcare products contributed 48.7%, 41.2%, 0.6% and 2.8%, respectively, of manufacturing segment revenue. OTC drugs contributed over 35%
- Consolidated the Group's leading position in the CHC¹ area by strengthening brand, forging advantage of quality brand clustering, and creating synergies between product, marketing and sales channel
- Established China's premier platform for chronic disease management and established separate chronic disease business unit to leverage its extensive operational experiences and wide channel coverage in this therapeutic area, and to strengthen its competitiveness and leading position




Strengthened Cooperation with MNCs, Accelerated Industrial Upgrade

- Manufacturing segment gross profit was HK\$21.4bn, decreased 1.7% YoY in terms of RMB, reported GP Margin 63.2%, 1.6 ppt lower YoY
- Continuously rejuvenated and professionalised the Group's OTC brands, accelerated merger and acquisition locally, proactively join the bidding of MNC's premium products' commercialisation and distribution right by leveraging the Group's extensive experience working with big MNCs ; During the reporting period, CR Sanjiu reached collaboration with Takeda Pharmaceutical (Japan), Nature's Care (Australia), and Ryukakusan Co. (Japan), etc.
- Proactively promoted intelligent manufacturing upgrade, based on "industrial automation + informatisation" to improve controllability of the manufacturing process from perspectives of process automation, informatisation of manufacturing process management, and interconnection
- Our product portfolios have the widest coverage of pharmaceutical products and therapeutic areas. We manufactured over 540 products, with about 300 included in the NDRL, and 142 in the National Reimbursement Drug List




Strengthened CHC brands, continuously refresh and professionalise OTC brands



Strengthened R&D Innovation, Integrated Biopharmaceutical Platform

- By the end of 2019, had more than 150 R&D projects in the pipeline, including 67 on innovative drugs. R&D expenditure was HK\$1.4bn in 2019
- During the reporting period, more than 64 key consistency evaluation projects had been commenced, 10 projects had commenced bioequivalence clinical trials, and 8 products had finished BE clinical trials; 7 products filed for reference drug qualification; 6 drugs (7 specifications) passed or were regarded as passing consistency evaluation; 6 products filed for manufacturing and registration application, 4 products were granted for drug manufacturing licenses
- During the reporting period, the Group integrated the biomedical platform by spinning-off CR Biopharm (founded in 2016) and directly holds shares in CR Angde Biotech Pharma, Protgen Pharmaceutical and Vector Gene Technology, in order to improve the manufacturing business layout. There are three products in the market: Bai Jie Yi, Rui Tong Li and Jia Lin Hao; There are 14 biological R&D stage products in the pipeline, out of that, 8 are innovative drugs and 6 are biosimilar drugs, mainly focusing on TAs of oncology, immunity and endocrine. The Group's newly developed Class I innovative drug NIP292 was approved by the U.S. Food and Drug Administration (FDA) for phase one clinical trials, and was granted the Orphan Drug Designation (ODD) in the U.S.



Including capitalized R&D expenditure

Innovative drug NIP292 was approved by the U.S. FDA for phase I clinical trials in the U.S.

Rui Tong Li has undergone evaluation for inclusion in the 2019 NRDL and was included into the Catalogue




Obtained 101 patents; Had over 800 R&D professionals



Azithromycin Tablets, Hydrotalcite Chewable Tablets, Metformin Sustained-Release Tablets, Finasteride Tablets (5mg), Levetiracetam Tablets (0.5g), Mifepristone Tablets (10mg&20mg) passed or regarded as passing consistency evaluation

Accelerated Channel Coverage, Transformed to Service Cooperation

- Distribution segment revenue in 2019 was HK\$170.7bn, increased 14.8%, higher than industry average growth rate
- Constantly enhanced channel coverage, with distribution network covering 28 provinces, municipalities and autonomous area, serving over 100,000 downstream customers, including approximately 7,000 Class II & III hospitals, more than 47,000 primary medical institutions and more than 46,000 retail pharmacies and other customers
- Continually develop modernised logistics supply chains featuring the competitive edge of integration, professionalisation, scaling and standardisation; By the end of 2019, the Group operated 178 logistics centres, owned a leading cold chain logistics management system and licensed to do third-party logistics for distribution of drug and medical device; During the reporting period, third-party logistics business revenue increased about 90% YoY
- Made progress in adjusting business model from mainly distribution to service cooperation; Officially set up subsidiary CR International Trading Limited for international business, established multilevel import system; Import drug distribution revenue was more than RMB10bn, increased more than 30% YoY






- Distribution segment gross profit was HK\$11.7bn, increased 7.7% YoY in terms of RMB, reported GP Margin 6.9%, 0.5 ppt lower YoY
- Optimised product portfolio, with increasing revenue contribution from distribution of medical device and Chinese herbal medicine; To promote professional development of medical device distribution business, we set up independent provincial medical device companies in 15 cities; Revenue of medical device distribution business increased over 50% YoY in 2019
- Ramped up efforts in premium products introduction, actively engaged with the distribution business of centralised procurement drugs, and collaborate with about 100 pharmaceutical enterprises whose products passed consistency evaluation; Accelerated introductions of premium oncology and innovative drugs; Introduced in 4 drugs included in NDRL through negotiations and 16 newly listed Class I innovation drugs to our product portfolio during the year
- Further developed and optimised our e-commerce platform, and get ready for the full open-up of online sales of prescribed drugs; By the end of 2019, CR Pharma e-store (潤藥商城) has gone live in 20 provinces with an annual transaction value of over RMB\$20bn; Explored CR Pharma Cloud Prescription model (潤藥云方), to achieve an orderly and two-way flow of prescription information, and get ready to undertake future business from prescription outflow from hospital.



Seized the Opportunity from Prescription Outflow, Integrated Retail Resources

- Retail segment revenue was HK\$6.5bn, or increased 23.8% YoY in terms of RMB, mainly benefiting from fast growing DTP business
- Segment GP Margin was 12.5%, 2.1 ppt lower YoY, mainly due to the relatively lower GP margin of fast growing DTP business
- Actively seized the business opportunity of prescription outflow from hospital, strengthened integration of retail resources, set up a centralised procurement platform, expanded businesses in e-commerce, TCM medical treatment and cross-border procurement
- By the end of 2019, operated 852 retail pharmacies, of which 175 are DTP pharmacies covering 89 cities nationwide, achieved revenue growth over 45% in terms of RMB




- 1 2019 Highlights
- 2 Business Review
- 3 **Financial Review**
- 4 2020 Strategy
- 5 Appendix




Key Financials


Revenue




Gross Profit



Operating Profit




Reported Net Profit attri. to Shareholders




Profit Margin and Operating Cash Flow


GP Margin & Operating Margin




Net Profit Ratio





Operating Expense Ratios




Net Cash from Operating Activities




Debt Ratio and Average Financing Cost



Gearing Ratio




Effective Interest Rate




Working Capital Turnover


Trade Receivable Turnover Days




Inventory Turnover Days



Trade Payable Turnover Days



Cash Conversion Cycle



- 1 2019 Highlights
- 2 Business Review
- 3 Financial Review
- 4 2020 Strategy
- 5 Appendix







Q&A

- 1 2019 Highlights
- 2 Business Review
- 3 Financial Review
- 4 2020 Strategy
- 5 Appendix



Appendix 1: Income Statement

HK\$ mn	2018	2019	YoY
Revenue	189,689	204,454	7.8%
Gross Profit	34,930	34,018	-2.6%
Gross Profit Margin	18.4%	16.6%	
Operating Profit	11,696	9,156	-21.7%
Operating Profit Margin	6.2%	4.5%	
Net Profit for the Company	7,572	5,098	-32.7%
Net Profit Attributable to Shareholders	3,978	3,286	-17.4%
Net Profit Margin Attributable to Shareholders	2.1%	1.6%	
EPS (HK\$)	0.63	0.52	

Appendix 2: Balance Sheet

HK\$ mn	2018 Dec 31	2019 Dec 31
Total assets	176,184	190,025
PPE	14,652	16,322
Goodwill	19,805	19,306
Trade and receivables	54,847	63,772
Inventories	21,528	22,332
Bank and cash	16,633	12,524
Total liabilities	115,715	120,443
Trade and other payables	56,198	60,077
Bank borrowings	40,665	31,066
Bonds payable	6,848	7,952
Total equity	60,469	69,582
Shareholders' equity	39,313	40,711
Current ratio	1.23	1.25
Total debt	53,951	52,134
Net debt	37,317	39,610
Net debt / total equity	0.62	0.57


Appendix 3: 2019 Performance by Segment

HK\$ mn	Manufacturing	Distribution	Retail	Others	Total
External Revenue	30,693	167,094	6,463	204	204,454
Segment results	6,765	7,736	73	142	14,717
Other income					1,886
Other gains & losses					(39)
Admin expenses					(5,204)
Other expenses					(1,261)
Share of profits of associates and joint ventures					140
Finance costs					(3,600)
Profit before tax					6,640

Principal Business

- A leading integrated pharmaceutical company in China
- Principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products

Shareholding Structure



¹ Beijing State-Owned Capital Operations and Management Centre (BSCOMC) is owned by Beijing SASAC

² By the close of market on 27 Mar 2020


Share Information

- Listed on the SEHK on 28 Oct 2016 (stock code: 3320.HK)
- Issued shares: 6,285mn¹
- Market cap: HK\$27.3bn²
- Inclusion in key capital market indices:
 - **FTSE Index Series**
 - Global Equity Index (Large Cap)
 - FTSE All-World Index
 - FTSE All Cap (LMS) Index
 - **Hang Seng Index Series**
 - Composite Large Cap Index
 - Mainland Healthcare Index
 - Healthcare Index
 - **CR Pharm and two of its A-share listed subsidiaries (CR Sanjiu/ Dong-E-E-Jiao) have been included in MSCI China Index**
 - **Hang Seng Stock Connect Hong Kong Index Series**
 - **Hang Seng Corporate Sustainability Benchmark Index**
 - **3 A-share listed subsidiaries (CR Sanjiu/CR Double-Crane/Dong-E-E-Jiao) have been included in FTSE Russell Global Index**



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited




Data as of 2019 December 30


Appendix 6: Corporate Structure

















華潤醫藥集團有限公司 China Resources Pharmaceutical Group Limited



Appendix 7: Development Milestones



Appendix 8: Chinese Medicine & Nutritional Products

Major Product	Therapeutic Area	Major Product	Therapeutic Area
 <p>E-Jiao block (阿胶块) and compound E-Jiao syrup</p>	Blood tonic	 <p>Tianhe-branded Gutong patch (骨通贴膏), Tianhe Zhuifeng ointment (天和追风膏), and the Zhuanggu product series (壮骨系列)</p>	Orthopedics
 <p>Ganmaoling (感冒灵) and Compound Ganmaoling (复方感冒灵), Qiangli Pipalu (强力枇杷露)</p>	Cold and cough remedies	 <p>Shenfu injection (参附注射液), Shenmai injection (参麦注射液) and Shengmai injection (生脉注射液)</p>	Cardiovascular system
 <p>The Zhengtian (正天) product series</p>	Headache	 <p>Huachansu (华蟾素) and Javanica oil soft capsule (鸦胆子油软胶囊)</p>	Oncology
 <p>Sanjiu Weitai (三九胃泰), Qizhi Weitong (气滞胃痛), and Yinzhihuang (茵栀黄)</p>	Alimentary tract and metabolism	 <p>A portfolio of Chinese medicine formula granules comprised of over 600 products</p>	Chinese medicine formula granules (中药配方颗粒)
 <p>Xiao'er Ganmao granules (小儿感冒颗粒) and Xiao'er Zhike syrup (小儿止咳糖浆)</p>	Pediatrics	 <p>Xuesaitong soft capsules (血塞通软胶囊)</p>	Cardiovascular system
 <p>Jianweixiaoshi tablets (健胃消食片) and Lacidophilin tablets (乳酸菌素片)</p>	Alimentary tract and metabolism	 <p>Taohuaji (桃花姬) and Zhen Yan E-Jiao Cake (真颜阿胶糕) derived from our E-Jiao Chinese medicine product series</p>	Nutritional product
 <p>Compound Caoshanhu tablets (复方草珊瑚含片)</p>	Oropharynx	 <p>Nutritional supplement and dietary supplement derived from core TCM</p>	Nutritional product

Appendix 9: Chemical Drugs

Major Product	Therapeutic Area	Major Product	Therapeutic Area
 <p>Compound Reserpine and Triamterene tablets (Hypertensive No. 0) (复方利血平氨苯蝶啶片(降压0号))</p>	Cardiovascular system	 <p>Cefazolin Sodium Pentahydrate for injection (Xintailin) (注射用五水头孢唑林钠 (新泰林))</p>	Anti-infectives
 <p>Amlodipine Besylate tablets (Yashida) (苯磺酸氨氯地平片(压氏达))</p>	Cardiovascular system	 <p>The peritoneal dialysis solution, or peritoneal dialysate</p>	Nephrology
 <p>Valsartan capsules (Suiyue) (缬沙坦胶囊(穗悦)) and Valsartan-Hydrochlorothiazide tablets (Fu Suiyue) (缬沙坦氢氯噻嗪片(复穗悦))</p>	Cardiovascular system	 <p>Calf Pulmonary Surfactant for injection (Kelisu) (注射用牛肺表面活性剂(珂立苏))</p>	Pediatrics
 <p>Pitavastatin Calcium tablets (Guanshuang) (匹伐他汀钙片(冠爽))</p>	Cardiovascular system	 <p>Pediatric Compound Amino Acid injection (小儿复方氨基酸注射液)</p>	Pediatrics
 <p>Gliquidone tablets (Tangshiping) (格列喹酮片(糖适平)) Metformin Sustained-release tablets (Buke) (二甲双胍缓释片(卜可))</p>	Alimentary tract and metabolism (Anti-diabetes)	 <p>Levonorgestrel tablets (左炔诺孕酮片), branded as Yuting and Golden Yuting</p>	Reproductive Health
 <p>Five basic types of IV solution container systems, namely glass bottle, plastic bottle, flexible bag, standing bag and BFS</p>	Large-volume IV infusion	 <p>Compound Dexamethasone Acetate cream (Piyanping) (复方醋酸地塞米松乳膏(皮炎平)) product series</p>	Dermatological Products